Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67


A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma.

Franken B, van de Donk NW, Cloos JC, Zweegman S, Lokhorst HM.

Ther Adv Hematol. 2016 Dec;7(6):330-344. Review.


Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?

Thumallapally N, Yu H, Asti D, Vennepureddy A, Terjanian T.

Onco Targets Ther. 2016 Aug 5;9:4843-58. doi: 10.2147/OTT.S110189. Review.


Specificity of Protein Covalent Modification by the Electrophilic Proteasome Inhibitor Carfilzomib in Human Cells.

Federspiel JD, Codreanu SG, Goyal S, Albertolle ME, Lowe E, Teague J, Wong H, Guengerich FP, Liebler DC.

Mol Cell Proteomics. 2016 Oct;15(10):3233-3242.


A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).

Hájek R, Masszi T, Petrucci MT, Palumbo A, Rosiñol L, Nagler A, Yong KL, Oriol A, Minarik J, Pour L, Dimopoulos MA, Maisnar V, Rossi D, Kasparu H, Van Droogenbroeck J, Yehuda DB, Hardan I, Jenner M, Calbecka M, Dávid M, de la Rubia J, Drach J, Gasztonyi Z, Górnik S, Leleu X, Munder M, Offidani M, Zojer N, Rajangam K, Chang YL, San-Miguel JF, Ludwig H.

Leukemia. 2017 Jan;31(1):107-114. doi: 10.1038/leu.2016.176.


Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance.

Hogan JJ, Weiss BM.

Clin J Am Soc Nephrol. 2016 Sep 7;11(9):1681-91. doi: 10.2215/CJN.03160316. Review.


Trial Watch: Proteasomal inhibitors for anticancer therapy.

Obrist F, Manic G, Kroemer G, Vitale I, Galluzzi L.

Mol Cell Oncol. 2014 Dec 1;2(2):e974463. doi: 10.4161/23723556.2014.974463. Review.


The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma.

Brown S, Hinsley S, Ballesteros M, Bourne S, McGarry P, Sherratt D, Flanagan L, Gregory W, Cavenagh J, Owen R, Williams C, Kaiser M, Low E, Yong K; Myeloma UK Clinical Trials Network..

BMC Hematol. 2016 May 17;16:14. doi: 10.1186/s12878-016-0053-9.


Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay.

Lee SJ, Levitsky K, Parlati F, Bennett MK, Arastu-Kapur S, Kellerman L, Woo TF, Wong AF, Papadopoulos KP, Niesvizky R, Badros AZ, Vij R, Jagannath S, Siegel D, Wang M, Ahmann GJ, Kirk CJ.

Br J Haematol. 2016 Jun;173(6):884-95. doi: 10.1111/bjh.14014.


A Tumor Growth Inhibition Model Based on M-Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single-Agent Carfilzomib Use.

Jonsson F, Ou Y, Claret L, Siegel D, Jagannath S, Vij R, Badros A, Aggarwal S, Bruno R.

CPT Pharmacometrics Syst Pharmacol. 2015 Dec;4(12):711-9. doi: 10.1002/psp4.12044.


A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma.

Watanabe T, Tobinai K, Matsumoto M, Suzuki K, Sunami K, Ishida T, Ando K, Chou T, Ozaki S, Taniwaki M, Uike N, Shibayama H, Hatake K, Izutsu K, Ishikawa T, Shumiya Y, Kashihara T, Iida S.

Br J Haematol. 2016 Mar;172(5):745-56. doi: 10.1111/bjh.13900.


Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity.

Cornell RF, Kassim AA.

Bone Marrow Transplant. 2016 Apr;51(4):479-91. doi: 10.1038/bmt.2015.307. Review.


Targeting ubiquitination for cancer therapies.

Morrow JK, Lin HK, Sun SC, Zhang S.

Future Med Chem. 2015;7(17):2333-50. doi: 10.4155/fmc.15.148. Review.


Myeloma today: Disease definitions and treatment advances.

Rajkumar SV.

Am J Hematol. 2016 Jan;91(1):90-100. doi: 10.1002/ajh.24236. Review. Erratum in: Am J Hematol. 2016 Sep;91(9):965.


Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.

Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Singhal S, Smith C, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R; National Comprehensive Cancer Network..

J Natl Compr Canc Netw. 2015 Nov;13(11):1398-435.


Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.

Das DS, Ray A, Song Y, Richardson P, Trikha M, Chauhan D, Anderson KC.

Br J Haematol. 2015 Dec;171(5):798-812. doi: 10.1111/bjh.13780.


David and Goliath: chemical perturbation of eukaryotes by bacteria.

Ho LK, Nodwell JR.

J Ind Microbiol Biotechnol. 2016 Mar;43(2-3):233-48. doi: 10.1007/s10295-015-1686-6. Review.


Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.

Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, Kaufman JL, Lentzsch S, Vogl DT, Gomes CL, Pascucci N, Smith DD, Orlowski RZ, Durie BG.

Blood. 2015 Nov 12;126(20):2284-90. doi: 10.1182/blood-2015-05-643320.


Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines.

Ao L, Reichel D, Hu D, Jeong H, Kim KB, Bae Y, Lee W.

J Pharmacol Exp Ther. 2015 Nov;355(2):168-73. doi: 10.1124/jpet.115.226993.


Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia.

Cole A, Wang Z, Coyaud E, Voisin V, Gronda M, Jitkova Y, Mattson R, Hurren R, Babovic S, Maclean N, Restall I, Wang X, Jeyaraju DV, Sukhai MA, Prabha S, Bashir S, Ramakrishnan A, Leung E, Qia YH, Zhang N, Combes KR, Ketela T, Lin F, Houry WA, Aman A, Al-Awar R, Zheng W, Wienholds E, Xu CJ, Dick J, Wang JC, Moffat J, Minden MD, Eaves CJ, Bader GD, Hao Z, Kornblau SM, Raught B, Schimmer AD.

Cancer Cell. 2015 Jun 8;27(6):864-76. doi: 10.1016/j.ccell.2015.05.004.

Items per page

Supplemental Content

Support Center